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Abstract
Background: The treatment paradigm in advanced renal cell carcinoma (RCC) has changed in the recent years.
Sunitinib has been established as a new standard for first-line therapy. We studied the prognostic significance of
baseline characteristics and we compared the risk stratification with the established Memorial Sloan Kettering
Cancer Center (MSKCC) model.
Methods: This is a retrospective analysis of patients treated in six Greek Oncology Units of HECOG. Inclusion
criteria were: advanced renal cell carcinoma not amenable to surgery and treatment with Sunitinib. Previous
cytokine therapy but no targeted agents were allowed. Overall survival (OS) was the major end point. Significance
of prognostic factors was evaluated with multivariate cox regression analysis. A model was developed to stratify
patients according to risk.
Results: One hundred and nine patients were included. Median follow up has been 15.8 months and median OS
17.1 months (95% CI: 13.7-20.6). Time from diagnosis to the start of Sunitinib (<= 12 months vs. >12 months, p =
0.001), number of metastatic sites (1 vs. >1, p = 0.003) and performance status (PS) (<= 1 vs >1, p = 0.001) were
independently associated with OS. Stratification in two risk groups ("low” risk: 0 or 1 risk factors; “high” risk: 2 or 3
risk factors) resulted in distinctly different OS (median not reached [NR] vs. 10.8 [95% confidence interval (CI): 8.3-
13.3], p < 0.001). The application of the MSKCC risk criteria resulted in stratification into 3 groups (low and
intermediate and poor risk) with distinctly different prognosis underlying its validity. Nevertheless, MSKCC model
did not show an improved prognostic performance over the model developed by this analysis.
Conclusions: Studies on risk stratification of patients with advanced RCC treated with targeted therapies are warranted.
Our results suggest that a simpler than the MSKCC model can be developed. Such models should be further validated.
Background
Renal cancer is the third most frequent malignancy of
the urinary tract and accounts for 3% of all adult malig-
nancies [1]. Most patients (70-80%) presenting with
localized disease can be cured with surgery. On the con-
trary, advanced disease or relapses after radical
nephrectomy is usually incurable. In total, nearly 50% of
patients with renal cell carcinoma will present with or
develop metastatic disease [1,2]. Prognosis in patients
with advanced disease remains poor and 5-year life
expectancy is less than 20% [2,3].
The cytokines Interleukin-2 (IL-2) and Interferon-a
(IFN-a) have been the standard of care in metastatic
RCC for more than fifteen years. This treatment
achieves low response rates, duration of response is
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any medium, provided the original work is properly cited.usually short and long-term survival is rare, while toxi-
city is considerable [4,5]. In spite of the above limita-
tions, some patients will benefit from cytokine
treatment. Retrospective analyses and the recently
reported PERCY Quattro trial [6] identified certain char-
acteristics, which allow for the selection of patients
likely to benefit from this treatment: LDH, Karnofsky
PS, nephrectomy, time from nephrectomy, calcium and
hemoglobin levels have been associated with indepen-
dent prognostic significance [6-9]. The combination of
these factors led to the development of a prognostic
model by the MSKCC including three patient groups
with a statistically significant and, more importantly,
clinically relevant difference in survival [8]. This model
was subsequently validated independently [10] and
proved valuable in selecting patients likely to benefit
from cytokine therapy and in interpreting results of
phase II and III studies.
Recent advances in our understanding of the biology
of RCC and especially the role of angiogenesis in the
development and expansion of this tumor led to the
development of novel targeted therapies [11-13], which
proved to be superior to interferon. Sunitinib is an inhi-
bitor of the split-kinase-domain family of receptor tyro-
sine kinases (including Vascular endothelial growth
factor-VEGF) [14]. Its antitumour activity results from
inhibition of angiogenesis through blockade of the
endothelial cell VEGF pathway and PDGFR-b expression
in pericytes but also tumour cell proliferation [15]. It
has been recently established as first-line treatment for
advanced RCC, following the results of a randomised
phase III trial, which showed a significant advantage
over interferon-a in progression-free survival (PFS) [11].
In spite of this undisputed benefit, the prognosis of
advanced RCC remains poor, while the toxicity of suni-
tinib (as well as that of other novel agents) is consider-
able [16]. There is, therefore, a need to select patients
likely to benefit from these therapies.
In contrast to cytokines, data on prognostic and pre-
dictive factors during treatment with sunitinib are lim-
ited. The MSKCC model has been used for the design
of all phase III trials using modern therapies. Neverthe-
less, there may be limitations associated with its use in
this context. This model was developed with patients
undergoing treatment with cytokines. Although it could
be argued that the factors used in this model reflect the
biological behavior of the disease, and, therefore, may be
applicable to any therapy, its utility in the context of tar-
geted therapies has not been fully evaluated. Further-
more, all randomized studies mainly included patients
with low or intermediate risk, i.e. populations with dif-
ferent composition than that of the population used to
develop the MSKCC model. Finally, the MSKCC model
has been validated as a predictor of OS, while PFS has
been the major end point in all randomized trials testing
targeted therapies. For the above reasons we analysed
the advanced RCC database of HECOG in order to
study prognostic clinicopathological factors in patients
treated with sunitinib. We also compared the prognostic
accuracy of the model, which was produced with that of
the MSKCC model in our population.
Methods
Patients
Since January 2008, clinicopathological data of patients
with advanced RCC treated with targeted agents have
been entered prospectively into a database of HECOG.
Data for patients treated with sunitinib after its approval
as first-line therapy in metastatic RCC in Greece (end of
2006) and prior to 2008 were retrieved from their medi-
cal records and were entered retrospectively. Patients had
given their written permission for the retrieval of data
from their medical records for research purposes prior to
the initiation of treatment. All patients were homoge-
nously treated and followed-up according to a protocol,
which was based on the approved SPC and the published
clinical studies. Sunitinib was administered at the
approved dose of 50 mg daily on a 4 weeks on-2 weeks
off schedule. Treatment was interrupted in case of Grade
3 or 4 toxicity and was reintroduced when toxicity was ≤
Grade 1. In case of Grade 3 non haematological toxicity
or Grade 4 haematological toxicity, there was a successive
reduction at a daily dose of 37.5 mg and 25 mg. Thyroid
dysfunction and arterial hypertension were managed with
appropriate medication without dose reductions. Tumor
evaluation was performed every 2-3 cycles of treatment
unless clinically indicated.
This is a retrospective analysis of patients treated with
sunitinib in six Greek Oncology Units of HECOG.
Inclusion criteria were: advanced RCC not amenable to
surgery and treatment with sunitinib. Adjuvant or first-
line treatment with interferon was allowed but no pre-
vious targeted therapy with sorafenib, bevacizumab or
temsirolimus. Measurable or evaluable disease was not
required for inclusion in the analysis. Data was frozen at
April 2009.
Statistical analysis
The SPSS software was used for statistical analysis (SPSS
for Windows, version 15.0, SPSS Inc.). OS was measured
from the date of randomization until death from any
cause. PFS was measured from the date of randomiza-
tion until objective tumor progression or death.
Time-to-event distributions were estimated using
Kaplan-Meier curves. The Cox proportional hazards
model was used to assess the relationship of OS with
various clinical and laboratory variables. The backward
selection procedure with removal criterion p > 0.10
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significant variables among the following: number of
metastatic sites (1 vs >1), time between diagnosis/sur-
gery and sunitinib initiation (<= 12 months vs >12
months), ECOG PS (<= 1 vs >1), Haemoglobin (<13 g/
dL vs >= 13 g/dL [Male]; <11.5 g/dL vs >= 11.5 g/dL
[Female]), Calcium (<10 vs >= 10), Lactate dehydrogen-
ase (normal vs abnormal), Alkaline phosphatase (normal
vs abnormal), prior nephrectomy (no vs yes).
A model was developed to stratify patients according
to risk. Significant risk factors were identified and model
selection was performed through Likelihood ratio tests,
comparing models to the established MSKCC models in
the literature [8,9]. The prognostic performance of the
models was assessed through ROC curves, and AUC
comparison was performed by a non-parametric test
proposed by DeLong [17]. STATA (version 10) was
used for the analysis.
Results
Patient characteristics
One hundred and nine patients (M: 80, F: 29; median
age 59) were included in this analysis. Their characteris-
tics are shown in Table 1. Seventeen patients (15%) had
been treated with IFNa 2a, while 86 (79%) had under-
gone nephrectomy. One hundred patients (91%) had
clear-cell carcinoma, while in another 3 (3%) a clear-cell
component with other elements was also detected. The
remaining cases were pure non clear-cell carcinomas. At
the time of analysis a total of 724 cycles of Sunitinib
had been administered (median 5, range 1-35).
Tumor response and PFS
Thirty-five patients (32%) were still on treatment.
Eighty-nine patients with at least one tumor evaluation
were assessable for response. Four patients experienced
early death prior to tumor assessment, while in the
remaining 16 cases no tumor assessment had been per-
f o r m e da tt h et i m eo fa n a l y s i s .O n ep a t i e n t( 1 . 1 % ,9 5 %
CI: 0.02-5) had complete tumor response (CR) and 19
patients (21.3%, 95% CI: 13.8-30.1) had a partial
response (PR) for a total of 22.4% objective response
rate (ORR). Stable disease (SD) was observed in 49 cases
(55.1%, 95% CI: 39.4-59.8), while 20 patients had pro-
gressive disease at first tumor evaluation (22.5%, 95%
CI: 14.2-30.9).
Median follow up was 15.8 months (range for surviv-
ing patients 0.1-31.5). Median PFS for the whole cohort
was 8.9 months (95% CI: 6.4-11.4), while 1-year PFS
rate was 40%.
Overall survival analyses
Median OS was 17.1 months (95% CI: 13.7-20.6) and
1-year survival rate 61%. During follow up 48 patients
Table 1 Characteristics of the 109 patients included in
the analysis
Age (Median, range) 59 30-79
n (%)
Sex
Male 80 (73)
Female 29 (27)
Nephrectomy
No 23 (21)
Yes 86 (79)
Time between diagnosis and Sutent initiation
<= 12 months 53 (49)
>12 months 54 (49)
Unknown 2 (2)
Histology
Clear Cell 100 (91)
Papillary 2 (2)
Chromophobe 2 (2)
Mixed 3 (3)
Unclassified 2 (2)
Performance Status
0 59 (54)
1 37 (34)
2 13 (12)
Number of Metastatic sites
1 32 (29)
>1 77 (71)
Site of metastatic disease
Lung 75 (69)
Nodes 38 (35)
Liver 10 (9)
Renal bed 27 (25)
Bones 39 (36)
Brain 8 (7)
Hb
Median (range) 12.1 (8.6-17.9)
<13 for Males, <11.5 for Females 57 (52)
>= 13 for Males, >= 11.5 for Females 50 (46)
Unknown 2 (2)
Ca
Median (range) 9.4 (1.0-12.1)
<10 85 (78)
>= 10 16 (15)
Unknown 8 (7)
LDH
Normal 58 (53)
Abnormal 38 (35)
Unknown 13 (12)
ALP
Normal 74 (68)
Abnormal 29 (27)
Unknown 6 (5)
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Page 3 of 12(44%) died from RCC. Univariate analysis showed that
the following factors were associated with worse OS: >1
metastatic sites (p = 0.004), <= 12 months between diag-
nosis and treatment with sunitinib (p = 0.001), PS >1
(p = 0.023), abnormal ALP (p = 0.004), low Hb levels
(p = 0.035) and no prior nephrectomy (p = 0.001)
(Table 2). The effect of LDH levels was not statistically
significant (p = 0.063), while previous therapy with IFN
or histological type did not affect OS (p = 0.217 and
p = 0.222, respectively). The independent association
with survival was examined in the backward selection
procedure. With a removal criterion of p > 0.10, the
final model for predicting survival included three inde-
pendent risk factors: number of metastatic sites, interval
from diagnosis/surgery to treatment initiation, and PS
(Table 3). The combination of these three factors
resulted in the stratification into 4 groups with distinct
separation of OS curves (Table 4, Figure 1).
Prognostic stratification and comparison with the MSKCC
model
The application of the MSKCC model, using stratifica-
tion by LDH, Hb, Ca, PS, time from diagnosis to initia-
tion of Sunitinib into 3 risk groups (favorable: 0 risk
f a c t o r s ,i n t e r m e d i a t e :1o r2r i s kf a c t o r s ,a n dp o o r :3 ,4
or 5 risk factors) (Model 1), resulted in populations with
distinctly separated OS curves (Table 4, Figure 2).
The breakdown of patients and events into the four
risk categories based on the identified risk factors and
how this corresponds to the breakdown to the three
MSKCC categories is presented in Table 5. Among the
15 patients in the favorable risk category by MSKCC
(death rate [DR]/year in observation = 0.05), no deaths
were observed for the six who were also identified as
belonging to the most favorable risk category by the
proposed model (DR = 0), while for the 9 who were
categorized in the second risk category by the proposed
model one of them died (DR = 0.07). Among the 25
patients with poor risk according to Motzer (DR =
0.95), for the patients in the least favorable risk category
by both models, all 6 patients died in a short period
(DR = 2.22 deaths per year in observation), while for the
remaining 19 patients categorized in the two intermedi-
ate risk categories according to the proposed model, 12
died during the observation period (DR = 0.74). Among
the 55 patients of the intermediate risk according to
Motzer (DR = 0.42), the DR according to the proposed
stratification was 0.08, 0.38 and 0.72, for the 9 patients
Table 2 Univariate Cox regression (OS)
Median OS (95% CI) HR (95% CI) p
Metastatic sites 0.004
1N R 1
>1 13.8 (10.4-17.3) 3.55 (1.50-8.36)
Time between diagnosis/surgery and Sunitinib initiation 0.001
<= 12 months 11.6 (8.2-14.9) 1
>12 months NR 0.36 (0.19-0.66)
Performance Status 0.023
<= 1 17.4 (10.2-24.6) 1
>1 7.6 (0-18.5) 2.32 (1.12-4.80)
Hb 0.035
<13 for Males, <11.5 for Females 14.3 (11.3-17.3) 1
>= 13 for Males, >= 11.5 for Females NR 0.51 (0.28-0.95)
Ca 0.538
<10 17.4 (8.3-26.6) 1
>= 10 15.1 (8.4-21.7) 1.29 (0.57-2.90)
LDH 0.063
Normal NR 1
Abnormal 13.8 (8.7-18.9) 1.78 (0.97-3.26)
ALP 0.004
Normal 22.3 1
Abnormal 10.7 (6.5-15) 2.46 (1.34-4.50)
Nephrectomy 0.001
No 8.9 (3.8-14.2) 1
Yes 22.3 0.36 (0.19-0.65)
NR: not reached
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the 20 with two risk factors, respectively. Thus, the
separation of the intermediate category in the MSKCC
model into the first three categories based on the pro-
posed stratification seems to offer better prognostic abil-
i t yf o rO Sa si st h ec a s ef o rt h ep o o ra n df a v o r a b l er i s k
categories.
The prognostic ability of the MSKCC model was
compared to the models based on the identified three
independent risk factors (number of metastatic sites,
interval from diagnosis/surgery to treatment initiation
and PS). These are the models with the three factors
(Model 2), and the models created by the combination
of them into 4 categories (number of risk factors pre-
s e n t :0 ,1 ,2 ,3-M o d e l3 ) ,i n t o3c a t e g o r i e sb yc o l l a p -
sing the two more favorable categories into one (Model
4), and finally into 2 categories by additionally collap-
sing the two less favorable categories into one (Model
5) (Table 3). Multivariate models 1-5 are presented in
Table 3. The prognostic ability of the proposed risk
stratification into either 4, 3 or 2 different categories
were compared to the MSKCC risk stratification. Areas
under the Curve (AUCs) for the corresponding ROCs
were 0.715, 0.686, 0.672, 0.661 for the 4, 3, 2, and
MSKCC risk categories respectively. The sensitivity and
specificity of each model were based on the predicted
probabilities of the corresponding logistic models at the
12 month follow-up time. No significant differences
were found. Figures 3 and 4 shows the resulting ROC
curves.
The model with stratification into 4 groups (Model 3)
seemed to be the more informative from all models pro-
posed (highest AUC = 0.715). Nevertheless, due to lack
of statistically significant differences and the small num-
ber of patients in each of the worst and best risk cate-
gories, the most parsimonious model (Model 5) with
only two risk categories (0 or 1 risk factors [n = 65] vs.
2 or 3 risk factors [N = 43], was chosen to be presented
here in more detail (Table 4, Figure 5). Descriptive sta-
tistics for OS in the 4 prognostic groups and the two
prognostic groups after collapsing the risk categories,
are presented in Table 4. For the final model 5, the
resulting difference in OS between the two risk cate-
gories was highly significant (P < 0.001). The hazard
ratio for the high-risk group is 3.63 (95% CI: 2.01-6.57)
compared to the low-risk group. One-year survival rates
for the two prognostic groups were: 74% and 42%,
respectively.
Table 3 Multivariate Cox regression (Survival)
HR 95% CI p
Model 1 MSKCC - Risk Group
Favourable 1 - -
Intermediate 8.06 1.09-59.59 0.041
Poor 18.21 2.42-136.88 0.005
Model 2 Metastatic sites
11 - -
>1 3.67 1.56-8.66 0.003
Time between diagnosis/surgery and Sunitinib initiation
<= 12 months 1 - -
>12 months 0.36 0.19-0.67 0.001
Performance Status
<= 1 1 - -
>1 3.04 1.46-6.32 0.003
Model 3 4-Groups
0 risk 1 - -
1 risk 5.64 0.75-42.39 0.093
2 risk 14.62 1.97-108.26 0.009
3 risk 51.20 6.09-430.42 0.000
Model 4 3-Groups
0 or 1 risk 1 - -
2 risk 3.26 1.76-6.06 0.000
3 risk 11.45 4.41-29.74 0.000
Model 5 2-Groups
0 or 1 risk 1 - -
2 or 3 risk 3.63 2.01-6.57 0.000
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stituting nephrectomy for interval from diagnosis/sur-
gery and exploring whether adding metastatic sites in
the Motzer model improves it, which was found to be
so (p = 0.001). Conclusions were not altered from these
analyses.
Discussion
Selection of patients with metastatic RCC likely to bene-
fit from antiangiogenic therapies represents an unmet
medical need. Preferably, a biological surrogate marker
which predicts for a favorable response to a targeted
agent should be used. At the moment, validated markers
do not exist, although certain positive associations have
been recently published [18-20]. Until the prospective
validation of such markers, selection of patients will rely
upon baseline clinicopathological characteristics of
patients who are candidates for targeted therapies.
In a retrospective analysis we assessed prognostic fac-
tors in a series of 109 patients. These patients have been
treated in six Oncology Units in Greece, outside clinical
studies, thus accurately reflecting the current clinical
practice in advanced RCC in our country. PFS and
ORR, based on investigator assessments, have been
reported for descriptive purposes. The median PFS of
8.9 months is similar to that reported for expanded
access programs (EAP) for sunitinib [21,22], taking into
consideration that our population included fewer
patients of favorable prognosis, according to MSKCC
criteria. ORR is lower than that reported in the
Table 4 Risk stratification based on the 3 independent prognostic factors found in multivariate analysis (number of
metastatic sites, time from diagnosis/surgery and PS) and the MSKCC criteria (LDH, Hb, Ca, PS, time from diagnosis/
surgery)
Stratification according to the risk factors identified in the current series
Risk factors Pts Events Censored (%) Mean OS (95% CI) Median OS (95% CI)
0 15 1 14 (93.3) 25.2 (22.5-27.8) NR
1 50 17 33 (66.0) 21.8 (18.2-25.3) NR
2 36 24 12 (33.3) 12.1 (9.7-14.4) 10.8 (9.5-12.2)
3 6 6 0 (0.0) 5.3 (1.4-9.1) 2.9 (0.9-4.9)
Total 107 48 59 (55.1) 18.7 (16.2-21.2) 17.1 (13.9-20.3)
Pairwise Comparison
No of risk factors 01 2 3
Chi-Square p Chi-Square p Chi-Square p Chi-Square p
0 3.680 .055 12.018 .001 22.564 .000
1 3.680 .055 9.368 .002 25.144 .000
2 12.018 .001 9.368 .002 7.969 .005
3 22.564 .000 25.144 .000 7.969 .005
Stratification in 2 prognostic groups
Risk factors Pts(%) Events Censored (%) Mean OS (95% CI) Median OS (95% CI)
0 or 1 65 18 47 (72.3) 23.5 (20.4-26.5) NR
2 or 3 43 30 13 (30.2) 11.3 (9.1-13.4) 10.8 (8.3-13.3)
Total 108 48 60 (55.6) 18.8 (16.3-21.3) 17.1 (13.9-20.3)
Stratification according to the MSKCC model
Risk factors Pts Events Censored (%) Mean OS (95% CI) Median OS (95% CI)
0 (favorable) 15 1 14 (93.3) 29.9 (26.7-33.0) NR
1,2 (intermediate) 56 24 32 (57.1) 19.1 (15.8-22.3) 17.4
3,4,5 (poor) 25 18 7 (28.0) 10.4 (7.9-12.8) 11.1 (3.9-18.4)
Total 96 43 53 (55.2) 18.9 (16.3-21.6) 15.1 (12.1-18.1)
Pairwise Comparisons
No of risk factors 0 1,2 3,4,5
Chi-Square Sig. Chi-Square Sig. Chi-Square Sig.
0 (favorable) 5.953 .015 16.052 .000
1,2 (intermediate) 5.953 .015 7.081 .008
3,4,5 (poor) 16.052 .000 7.081 .008
NR: not reached
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Page 6 of 12Figure 1 Overall survival according to risk factors (0-3) found in our analysis.
Figure 2 Overall survival according to the MSKCC criteria.
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Page 7 of 12randomized study by Motzer et al [11], which is again
consistent with the data from EAPs. It should also be
noted that 32% of our patients were still on treatment,
which may have resulted in underestimation of the
ORR, as suggested by a recent analysis showing a higher
R Ra f t e rl o n g e rf o l l o wu p[ 2 3 ] .T h ea b o v ed a t as u g g e s t
that our cohort is a representative population treated
with Sunitinib worldwide.
Certain limitations should be taken into considera-
tion in relation to this analysis. We included patients
previously treated with IFN and with non-clear cell
histology (15% and 4% of the total, respectively).
Nevertheless, these characteristics were not associated
w i t hp r o g n o s i s ,a sa l s os h o w ni na nI t a l i a nE A P[ 2 2 ] .
Finally, the median follow up is fairly short to estimate
long-term survival in our cohort. The patients are still
on follow up and long-term survival will be reported
upon maturation.
Median OS for the whole cohort was 17.1 months.
This is somewhat lower than that reported in the two
EAPs, probably reflecting the low proportion of favor-
able prognosis patients (according to the MSKCC cri-
teria) included in our cohort. This is the first analysis of
prognostic factors regarding OS in unselected patients
treated with sunitinib. Although PFS has become an
established end point for assessing new agents in RCC,
we believe that OS should still remain the major end
point in studying prognostic factors in unselected
patients. Especially in retrospective analyses, PFS is
based on investigators’ assessments and time of efficacy
assessment may vary. In addition, the application of
RECIST criteria for defining progression may not be
adequate in the era of targeted therapies [24]. The use
of PFS as a major end point for analysis of prognosis is
justified in randomized studies which allow crossover to
am o r ee f f e c t i v et h e r a p y ,w h i c hm a yh a v ea ni m p a c to n
survival. In our cohort, this concern would be justifiable
if patients had received such therapy upon progression
on Sunitinib. Although there is evidence that targeted
therapies may be effective after the failure of each other,
only everolimus has proven prolongation of PFS benefit
after Sunitinib [25]. This agent is not yet available in
Greece.
The analysis of survival data in unselected patients
may be of value for groups, which are underrepresented
in large studies, such as poor risk patients according to
MSKCC criteria. The value of sunitinib in this group is
not clarified. We showed a median OS of 11.2 months
in 25 patients of this category. This is a promising
result, taking into consideration the median of 5 months
shown for IFN [9] and 7 months reported for Temsiroli-
mus [26], which is considered the current standard for
these patients. Although these are indirect comparisons,
our result supports subgroups analyses performed in the
context of a randomized study [11], suggesting that
sunitinib is effective in poor risk patients.
Table 5 Breakdown of patients, events, total observation time (in years) and death rate according to the 4 risk
category proposed model and the MSKCC model.
Events/Patients Proposed model
0 risk 1 risk 2 risk 3 risk Total
MSKCC model Favorable risk 0/6 1/9 0/0 0/0 1/15
Intermediate risk 1/9 10/26 13/20 0/0 24/55
Poor risk 0/0 3/5 9/14 6/6 18/25
Total 1/15 14/40 22/34 6/6 43/95
Events/Total observation time (in years)
1 Proposed model
0 risk 1 risk 2 risk 3 risk Total
MSKCC model Favorable risk 0/5.5 1/14.5 0/NA 0/NA 1/20
Intermediate risk 1/12.7 10/26.3 13/18.1 0/NA 24/57.1
Poor risk 0/NA 3/5.1 9/11.2 6/2.7 18/19
Total 1/18.2 14/45.9 22/29.3 6/2.7 43/96.1
Total observation time (in years)
1
(Death rate per year in observation)
Proposed model
0 risk 1 risk 2 risk 3 risk Total
MSKCC model Favorable risk 5.5 (0) 14.5 (0.07) NA NA 20 (0.05)
Intermediate risk 12.7 (0.08) 26.3 (0.38) 18.1 (0.72) NA 57.1 (0.42)
Poor risk NA 5.1 (0.59) 11.2 (0.80) 2.7 (2.22) 19 (0.95)
Total 18.2 (0.05) 45.9 (0.30) 29.3 (0.75) 2.7 (2.22) 96.1 (0.45)
1Defined as the time up to last contact or death
2NA: Not applicable due to non-existing cases in these categories
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Page 8 of 12Figure 3 ROC curves comparing the MSKCC model with the model developed by our analysis.
Figure 4 ROC curves comparing the MSKCC model with the final model resulting after the collapse of four risk groups into two.
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Page 9 of 12We identified time from diagnosis to start of Suniti-
nib, number of metastatic sites and PS as independent
prognostic factors. The prognostic significance of these
factors has been previously identified in patients treated
with cytokines [8,9], indicating that they are associated
with the behavior of the disease rather with a specific
form of therapy. The combination of these factors
resulted in two groups with statistically and clinically
significant difference in outcome. It should be noted
that the collapsing of the initial four risk groups (0,1,2
or 3 risk factors) into the final two was largely the result
of the relatively small sample size, which represents a
limitation of this analysis. Given the heterogeneity of
mRCC, separation into more risk groups may be more
informative as indeed was suggested by our statistical
analysis. For these reasons, we plan to further study and
validate our model in larger cohorts of patients. We
compared our model with the established MSKCC
m o d e l .T h eu s eo fad i f f e r e n tt h e r a p yf r o mc y t o k i n e s
may have an impact on the prognostic significance of
certain factors included in that model. In a recent analy-
sis of the 375 patients receiving first-line sunitinib in
the context of the randomized study [11], the same fac-
tors plus the presence of bone metastases were found to
be prognostically significant for OS [27]. The application
of this model to our population resulted in 3 prognosti-
cally distinct groups, which underlines its validity.
Nevertheless, further improvement may be possible.
This model uses 2 clinical factors (time from diagnosis
to the start of systemic therapy and PS) and 3 laboratory
parameters (corrected calcium, hemoglobin and LDH).
The use of laboratory parameters makes retrospective
classification of patients with missing data impossible
and this might represent an advantage of our prognostic
algorithm. More importantly, the distribution of patients
according to the MSKCC model is uneven: almost 60%
of the population belonged to the intermediate risk
group [9,10]. The disproportionately large number of
patients in this group suggests that it may be somewhat
heterogeneous in respect to outcome. On the contrary,
the two groups of our model had a more even distribu-
tion. The breakdown of the 55 intermediate risk patients
of the MSKCC group according to our model resulted
in two groups of 35 and 20 patients with a more than
2-fold difference in the annual death rate, suggesting a
clinically meaningful prognostic separation of this
group. The comparison of the MSKCC model with our
model showed no significant differences. For the above
reasons, we believe that further validation of our model
is warranted.
Figure 5 Overall survival after stratification in low and high risk patients according to the final model.
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Page 10 of 12Conclusions
Our study indicates that simple prognostic models,
based on clinical factors, may apply to metastatic RCC
treated with sunitinib and further studies to validate
such models are warranted. These models may be sub-
stituted for the widely applied MSKCC model.
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